December 13, 2018
Otsuka Pharmaceutical said on December 11 that its US subsidiary Avanir Pharmaceuticals has agreed to cease a license deal with US-based Optinose for the development and commercialization rights to Optinose’s intranasal acute migraine treatment Onzetra Xsail (sumatriptan). Under the license...read more